Next 10 |
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
2024-07-05 07:18:27 ET More on Roche Roche: Obesity Treatment's Promise Isn't Enough More Of The Same Isn't Good Enough For Roche Roche Is Joining The Obesity Party But Questions Remain Roche's crovalimab wins FDA approval for paroxysmal nocturnal hemoglobinu...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 45 th Annual ...
2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...
2024-06-04 14:00:07 ET Peter Lawson from Barclays issued a price target of $35.00 for RCUS on 2024-06-04 09:49:00. The adjusted price target was set to $35.00. At the time of the announcement, RCUS was trading at $16.15. The overall price target consensus is at $42.00 wi...
2024-06-03 14:01:03 ET More on Gilead Sciences, Arcus Biosciences Gilead Sciences: Seriously Undervalued At Peak Pessimism Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO ...
– In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk of Disease Progression by 73% Compared to Regorafenib in a Phase 1b/2 Trial – – Results will be Prese...
– Data Support the Ongoing Phase 3 STAR-221 Study of Domvanalimab Plus Zimberelimab and Chemotherapy, Potentially the First Anti-TIGIT Combination to Market for These Cancers – – Results will be Presented Today During an Oral Session at the ASCO Annual Meeting ...
2024-05-26 08:05:48 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 45 th Annual ...